Bain Capital Public Equity Management II’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bain Capital Public Equity Management II’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-343,152	Closed	-$27.4M	–	54
2022 Q2	$27.4M	Sell	343,152 -943,219	-73%	-$89.3M	1.35%	23
2022 Q1	$135M	Buy	1,286,371 +638,875	+99%	+$62.3M	4.33%	6
2021 Q4	$69.8M	Sell	647,496 -243,874	-27%	-$26.6M	2.33%	19
2021 Q3	$97.6M	Buy	891,370 +4,046	+0.5%	+$420K	3.41%	13
2021 Q2	$83.1M	Sell	887,324 -78,727	-8%	-$7.24M	3.55%	12
2021 Q1	$88.9M	Sell	966,051 -99,250	-9%	-$8.38M	3.7%	10
2020 Q4	$77.9M	Buy	1,065,301 +783,253	+278%	+$58.2M	3.98%	7
2020 Q3	$21.9M	Buy	+282,048	New	+$19.4M	1.45%	24
2020 Q2	–	Sell	-27,522	Closed	-$815K	–	60
2020 Q1	$815K	Buy	+27,522	New	+$931K	0.1%	36
2019 Q4	–	Sell	-625,270	Closed	-$17M	–	62
2019 Q3	$17M	Buy	+625,270	New	+$16.2M	1.62%	17

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bain Capital Public Equity Management II's HZNP Position: Q3 2022 in Review

Bain Capital Public Equity Management II sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 343,152 shares — an estimated $27.4M sold.

Bain Capital Public Equity Management II first reported a position in HZNP in Q3 2019 and held it in 10 quarters. The position peaked at $135M in Q1 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Bain Capital Public Equity Management II reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Bain Capital Public Equity Management II sold 343,152 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $27.4M.
Bain Capital Public Equity Management II first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 10 quarters.
Bain Capital Public Equity Management II's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $135M in Q1 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Bain Capital Public Equity Management II's 13F filing for Q3 2022, filed 14 Nov 2022.